NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/10/2026 15:35
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5,300.69 mln
Float84.45 mln
Earnings Date11/04/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-4.6
Highly reliable
1-Year Forecast
87.56
Transformational upside
Relative Strength
13
/ 100
Significantly lagging
Debt / Equity
0.45
Low leverage
Pre-Tax Margin
-4,074%
Severely loss-making
Business Description
CRISPR Therapeutics AG is a Swiss biotechnology company founded in 2013 that develops treatments for serious diseases by precisely modifying patients' DNA. Its most advanced product, CASGEVY, has been approved to treat sickle cell disease and beta-thalassemia by editing a patient's own stem cells to restore healthy red blood cell function. The company is also advancing a broad pipeline of therapies targeting blood disorders, cancer, autoimmune conditions, cardiovascular disease, and type 1 diabetes, with key programs built around engineered immune cell treatments and direct gene correction inside the body. CRISPR Therapeutics works alongside Vertex Pharmaceuticals and operates from its headquarters in Zug, Switzerland.
